1. The use of an IBAT inhibitor and a bile acid binder, wherein the bile acid binder is formulated to be released in the colon to produce a combination for simultaneous, sequential or separate administration to produce an IBAT inhibitory effect in a warm-blooded animal such as a human. The use of claim 1, wherein the combination is for delivering an IBAT inhibitor to the small intestine and a bile acid binder to the colon. The use according to claim 1 or 2, where the IBAT inhibitor is a compound selected from the group consisting of benzothiepines, 1,4-benzothiazepines, 1,5-benzothiazepines and 1,2,5-benzothiazepines, which are active in screening for inhibiting IBAT properties. 4. The use according to claim 1, wherein the IBAT inhibitor is a compound of formula II: wherein M is —CH or NH； R is H or OH； and R is H, —CH, —CHCH, —CHCHCH, —CHCHCHCH, —CH (CH), —CHCH (CH), —CH (CH) CHCH, —CHON, —CHOCCH, —CH (OH) CH, —CHSCH, or - CHCH-S-CH； or a pharmaceutically acceptable salt thereof. 5. The use according to claim 4, wherein the compound of formula (II) is selected from 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -α- [N- (carboxymethyl ) carbamoyl] benzyl} carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine； 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -α- [N ′ - ((S) -1-carboxyethyl) carbamoyl] benzyl} carbamoylmethoxy) -2,3,4,5-tetrahydro-1,5-benzothiazepine； 1,1-dioxo 3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -α- [N - ((S) -1-carboxypropyl) carbamoyl] benzyl} carbamoylmethoxy) -2,3,4 , 5-tetrahydro-1,2,5-benzothiadiazepine； 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N - {(R) -α- [N - (( R) -1-carboxy-2-methylthioethyl) carbam yl] benzyl} carbamoylmethoxy) -2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine； 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- (N- {(R) -α- [N - ((S) -1-carboxy�1. Применение ингибитора IBAT и связующего желчной кислоты, где связующее желчной кислоты сформулировано для высвобождения в ободочной кишке для
